Evaluate non-inferiority and persistence of the immune response of GSK Biologicals' meningococcal vaccine 134612 versus Meningitec or Mencevax ACWY in healthy subjects (1-10 years of age).

Trial Profile

Evaluate non-inferiority and persistence of the immune response of GSK Biologicals' meningococcal vaccine 134612 versus Meningitec or Mencevax ACWY in healthy subjects (1-10 years of age).

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group C conjugate; Meningococcal vaccine groups A C W-135 polysaccharide; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Meningococcal infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Jul 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
    • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top